How many years can Almonertinib be taken and recommendations for safe use?

Almonertinib (Almonertinib) is a new third-generation EGFR tyrosine kinase inhibitor (< span>TKI), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Clinical data shows that the drug can effectively inhibit T790M drug-resistant mutations and improve patients' progression-free survival (PFS) and overall survival (OS). Regarding the duration of taking, there is currently no strict rule of years. The treatment principle is mainly determined based on disease control and tolerance. In clinical practice, long-term continuous administration of ametinib is feasible as long as the patient tolerates it well and the tumor does not progress.

During long-term medication, patients need regular reexamination and follow-up. Including imaging examinations (such as CT or MRI), hematological indicators, liver and kidney function and cardiac function monitoring to detect disease progression or adverse drug reactions in a timely manner. Clinically, it is recommended to review every 3-6 months. If tumor progression or intolerable adverse reactions occur, you should promptly discuss with your doctor whether to adjust the dose or change the treatment plan. For elderly patients or those with abnormal liver and kidney function, more caution should be exercised. If necessary, the reexamination interval can be appropriately extended and drug metabolism can be monitored.

Recommendations for the safe use of ametinib mainly include the correct method of taking it and preventing common side effects. The medicine should be taken orally once a day as directed by the doctor, and the intervals should be as fixed as possible to avoid missing doses. Common adverse reactions include rash, diarrhea, fatigue, mild to moderate liver function abnormalities, etc., most of which are within the controllable range. Patients should maintain good living habits, such as regular work and rest, a balanced diet and avoid overexertion. At the same time, they should avoid taking drugs that may cause drug interactions, such as strong CYP3A4 inhibitors or inducers, to ensure stable blood drug concentrations.

Overall, ametinib can be taken long-term as long as the patient tolerates it well and the disease does not progress. The key to safe management is regular review, close monitoring of adverse reactions, and strict compliance with physician medication instructions. In the event of obvious side effects or disease progression, the plan should be adjusted in a timely manner. Through scientific long-term management, Ametinib can control tumor progression while trying to protect patients' quality of life, making long-term treatment a feasible and effective solution.

Reference link:https://www.drugs.com